STOCK TITAN

Medexus Pharmaceuticals Inc. - $MEDXF STOCK NEWS

Welcome to our dedicated page for Medexus Pharmaceuticals news (Ticker: $MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medexus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medexus Pharmaceuticals's position in the market.

Rhea-AI Summary

Medexus Pharmaceuticals and medac have concluded the litigation regarding the Canadian patent for Metoject® after a trial in January 2023. The Federal Court of Canada declined to uphold the patent, leading to no meaningful changes for Medexus's business. The company remains optimistic about the impact of this outcome on their product and operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
none
-
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announces participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference. Company executives to present on April 17, 2024, at 1:30 PM Eastern time in Toronto, Ontario.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
conferences
-
Rhea-AI Summary
Medexus Pharmaceuticals receives FDA approval for expanded indication of IXINITY for pediatric patients under 12 years of age with hemophilia B, based on Phase 3/4 data showing safety and efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
News
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced its operating and financial results for the third fiscal quarter ended December 31, 2023. The company reported a revenue of $25.2 million and $87.1 million for the three- and nine-month periods, with a decrease of $3.5 million and an increase of $7.6 million compared to the same periods in 2022. The adjusted EBITDA was $3.2 million and $15.1 million for the three- and nine-month periods, showing a decrease of $2.0 million and an increase of $3.8 million compared to the prior year. The available liquidity was $8.2 million as of December 31, 2023, and the operating income was $1.6 million and $10.0 million for the three- and nine-month periods, with a decrease of $1.3 million and an increase of $5.1 million compared to the previous year. The net loss was $0.5 million and $1.0 million for the three- and nine-month periods, indicating an improvement of $1.0 million and $4.6 million compared to the same periods in 2022. Adjusted net loss showed an improvement as well, with $0.5 million and $1.1 million for the three- and nine-month periods, compared to $0.9 million and $7.3 million for the same periods in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.5%
Tags
-
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) will host a conference call on February 8, 2024, to discuss its third fiscal quarter results. Financial statements and MD&A will be filed on February 7, 2024. The call will be available via webcast and replay, with access details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
-
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announces Health Canada's acceptance for review of their new drug submission for terbinafine hydrochloride nail lacquer to treat fungal nail infections, aiming for a commercial launch in the first half of calendar year 2025. The Canadian topical fungicides market is estimated to be C$88 million annually, positioning the product for significant market potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
none
Rhea-AI Summary
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) announced a 9.4% increase in fiscal Q2 2024 revenue over fiscal Q2 2023, reaching $30.3 million. Adjusted EBITDA rose by 26.2% to $5.3 million, while operating income increased by $1.7 million. However, the net loss improved by $1.6 million. Medexus also secured $37.5 million in liquidity, utilizing it to repay convertible debentures and complete a bought-deal public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
-
Rhea-AI Summary
Medexus Pharmaceuticals plans to host a conference call on November 9, 2023, to discuss its second fiscal quarter results. The company expects to file its financial statements and MD&A on November 8, 2023. Participants can join the call through dial-in numbers or access the live webcast on Medexus's corporate website. A replay of the call and webcast will be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
All director nominees reelected and all other company proposals approved by shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
Rhea-AI Summary
Medexus Pharmaceuticals expects to fully satisfy convertible debentures in cash at maturity in October 2023 with the help of a $18 million increase in BMO's term loan commitment. The company's cash position and liquidity will be improved, allowing them to make the maturity date payment entirely in cash if they choose to do so. The weighted average interest rate on the credit facilities is 8.68%, which is lower than the previous rate of 9.02%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
none
Medexus Pharmaceuticals Inc.

OTC:MEDXF

MEDXF Rankings

MEDXF Stock Data

28.23M
20.59M
8.69%
11.35%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Verdun